Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans

Current Opinion in Lipidology

Volumn 11, Issue 3, 2000, Pages 261-266

  Marsh, Julian B ^a   Welty, Francine K ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; STABLE ISOTOPE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; LOW FAT DIET; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; METHODOLOGY; PRIORITY JOURNAL; RECYCLING; REVIEW; RISK;

AMINO ACIDS; APOLIPOPROTEIN A-I; DIET; FEMALE; HUMANS; ISOTOPES; LIPOPROTEINS, HDL; MALE;

EID: 0034034147     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200006000-00006     Document Type: Review

References (39)

1. 1 Watson TD. New in-vivo techniques for measuring lipoprotein metabolism. Curr Opin Lipidol 1995; 6:182-186.
2. 2 Rader DJ, Ikewaki K. Unravelling high density lipoproteinapolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol 1996; 7:117-123.
3. 3 Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993; 91:1743-1752.
4. 4 Colvin PL, Moriguchi E, Barrett PH, Parks JS, Rudel LL. Small HDL particles containing two apoA-I molecules are precursors in vivo to medium and large HDL particles containing three and four apoA-I molecules in nonhuman primates. J Lipid Res 1999; 40:1782-1792. This paper shows that apoA-I once incorporated into an HDL particle does not exchange with other particles. It also supports the kinetic evidence in humans (see Ref. 21) for the removal from the circulation of some newly synthesized HDL particles and their subsequent re-entry after peripheral sequestration.
5. 5 Fisher WR, Venkatakakrishnan V, Fisher ES, Stacpoole, PW, Zech LA. The 3H leucine tracer: its use in kinetic studies of plasma lipoproteins. Metabolism 1997; 46:333-342.
6. 6 Demant T, Packard CJ, Demmelmair H, Stewart P, Bedynek A, Bedford D, Shepherd J. Sensitive methods to study human apolipoprotein B metabolism using isotope-labeled amino acids. J Am J Physiol 1996; 270:E1022-E1036.
7. 7 Parhofer KG, Barrett PHR, Bier DM, Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 1991; 32:1311-1323.
8. 15N]glycine precursor enrichment. J Lipid Res 1989; 30:841-846.
9. 9 Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Schaefer EJ. Human apolipoprotein (Apo) B-48 and apoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol 1999; 19:2966-2974.
10. 10 Green PHR, Glickman RM, Saudek CD, Blum CB, Tall AR. Human intestinal lipoproteins. Studies in chyluric subjects. J Clin Invest 1979; 64:233-242.
11. 11 Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer Jr HB. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 1993; 34:2207-2215.
12. 12 Slum CB, Levy R, Eisenberg S, Hall M, Goebel R, Berman M. High density lipoprotein metabolism in man. J Clin Invest 1977; 60:795-807.
13. 13 Zech LA, Schaefer EJ, Bronzert TJ, Aamodt RL, Brewer Jr HB. Metabolism of human apolipoproteins A-I and A-II: compartmental models. J Lipid Res 1983; 24:60-71.
14. 14 Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer Jr HB, Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal women. J Clin Endocrinol Metab 1983; 57:262-267.
15. 15 Rader DJ, Castro G, Zech LA, Fruchart JC, Brewer Jr HB. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I, A-II. J Lipid Res 1991; 32:1849-1859.
16. 16 Tilly-Kiesi M, Lichtenstein AH, Li Z, Dolnikowski GG, Lamon-Fava S, Schaefer EJ. Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpAI and LpAI:AII in older subjects. Arterioscler Thromb Vasc Biol 1997; 17:3513-3518.
17. 17 Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I FCR, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein upases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994; 14:707-720.
18. 18 Foster DM, Barrett PHR, Toffolo G, Beltz WF, Cobelli C. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res 1993; 34:2193-2205.
19. 19 Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990; 85:804-811.
20. 20 Lichtenstein AH, Cohn JS Hachey DL, Millar JS, Ordovas JM, Schaefer EJ. Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-I and B-100 kinetics. J Lipid Res 1990; 31:1693-1701.
21. 21 Fisher WR, Venkatakrishnan V, Zech LA, Hall CM, Kilgore LL, Stacpoole PW, et al. Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. J Lipid Res 1995; 36:1618-1628.
22. 22 Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher DW, Drobnik W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-351. The gene defect responsible for the orange tonsils and the extremely low HDL levels of classical Tangier disease has now been discovered. More than one mutation has been described (see the following two refs, 23 and 24).
23. 23 Rust S, Rosier M, Funke H, Real K, Amoura Z, Piette J-C, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352-355.
24. 24 Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci USA 1999; 96:12685-12690.
25. 25 Vélez-Carrasco W, Lichtenstein AH, Welty FK, Li Z, Lamon-Fava S, Dolnikowski GG, Schaefer EJ. Dietary restriction of saturated fat and cholesterol decreases HDL apoA-I secretion. Arterioscler Thromb Vasc Biol 1999; 19:918-924. A first step in understanding the mechanism of dietary effects on HDL levels.
26. 26 Brinton EA, Eisenberg S, Breslow JL. A low-fat diet diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest 1990; 85:144-151.
27. 3-leucine in middle aged and elderly men and women. Arterioscler Thromb Vasc Biol 2000; 20: 801-806. This study highlights the role of apoA-I and apoA-II secretion rates in determining plasma levels and relates plasma TG levels to HDL size and apoA-I catabolism.
28. 28 Frenais R, Ouguerram K, Maugeais C, Marchini JS, Benlian P, Bard JM, et al. Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res 1999; 40:1506-1511.
29. 29 Frenais R, Ougerram K, Maugeais C, Mahot P, Maugere P, Krempf M, Magot T. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia 1997; 40:578-583.
30. 30 Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998; 47:1928-1934. This paper links the arteriosclerosis risk of insulin resistance with HDL catabolism.
31. 31 Vélez-Carrasco W, Lichtenstein AH, Barrett PHR, Sun Z, Dolnikowski GG, Welty FK, Schaefer EJ. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins. J Lipid Res 1999; 40:1695-1700. This study shows that apoA-I within TRL is not catabolized along with apoB48 of TRL but has a FCR similar to that of HDL.
32. 32 Millar JS, Lichtenstein AH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Proposal of a multicompartmental model for use in the study of apolipoprotein E metabolism. Metabolism 1998; 47:922-928. The results obtained with a best-fit compartmental model show rapid removal of apoE from the TRL fraction.
33. 33 Gregg RE, Zech LA, Schaefer EJ. Apolipoprotein E metabolism in normolipidemic human subjects. J Lipid Res 1984; 25:1167-1176.
34. 34 Verges B, Rader D, Schaefer J, Zach L, Kindt M, Fairwell T, et al. In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study. J Lipid Res 1994; 35:2280-2291.
35. 35 Malmendier CL, Lontie JF, Lagrost L, Delcroix C, Dubois DY, Gambert P. In vivo metabolism of apolipoproteins A-IV and A-I associated with high density lipoprotein in normolipidemic subjects. J Lipid Res 1991; 32:801-808.
36. 36 Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103:1191-1199.
37. 37 Lamarche B, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 1999; 286:145-161. A thorough review of metabolic mechanisms linking low HDL with high triglycerides.
38. 38 Krieger M, Kozarsky K. Influence of the HDL receptor SR-B1 on atherosclerosis. Curr Opin Lipidol 1999; 10:491-497.
39. 39 Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, et al. The intrinsic factor-vitamin B12 receptor, cubulin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999; 5:656-661. An important second function for this classical receptor involves the renal catabolism of apoA-I.